Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Sacks Hasegawa as Vice President after Business Improvement Order
The Japan Pharmaceutical Manufacturers Association (JPMA) has dismissed Takeda Pharmaceutical Chairman Yasuchika Hasegawa as its vice president after the company faced a business improvement order for running improper advertisements. At a press conference following its board meeting on July 2,…
To read the full story
Related Article
- JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
May 29, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
- Japan Govt OKs FY2015 Tax Reform Plan
January 15, 2015
- JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
September 19, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
ORGANIZATION
- Keidanren Calls for English Drug Filings to Be Opened to Japan-Based Firms
September 16, 2026
- JPWA Disbands Kumamoto Quake Disaster Response HQ
September 14, 2026
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…